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Abstract
A risk score was recently derived to predict mortality in adult patients with Gram-negative bloodstream infection (BSI). The aim of this
study was to provide external validation of the BSI mortality risk score (BSIMRS) in a population-based cohort. All residents of Olmsted
County, Minnesota, with Escherichia coli and Pseudomonas aeruginosa BSI from 1 January 1998 to 31 December 2007 were identiﬁed. Logistic
regression was used to examine the association between BSIMRS and mortality. Area under receiver operating characteristic curve (AUC)
was calculated to quantify the discriminative ability of the BSIMRS to predict a variety of short-term and long-term outcomes. Overall,
424 unique Olmsted County residents with ﬁrst episodes of E. coli and P. aeruginosa BSI were included in the study. Median age was 68
(range 0–99) years, 280 (66%) were women, 61 (14%) had cancer and 9 (2%) had liver cirrhosis. The BSIMRS was associated with 28-day
mortality (p <0.001) with an AUC of 0.86. There was an almost 56% increase in 28-day mortality for each point increase in BSIMRS
(OR 1.56, 95% CI 1.40–1.78). A BSIMRS ≥5 had a sensitivity of 74% and a speciﬁcity of 87% to predict 28-day mortality with a negative
predictive value of 97%. The BSIMRS had AUC of 0.85, 0.85 and 0.81 for 7-, 14- and 365-day mortality, respectively. BSIMRS stratiﬁed
mortality with high discrimination in a population-based cohort that included patients of all age groups who had a relatively low prevalence
of cancer and liver cirrhosis.
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Introduction
Bloodstream infection (BSI) is a major cause of morbidity and
mortality in Europe and North America with 1.8 million
episodes of BSI and 250 000 deaths annually [1]. Gram-
negative bacilli account for nearly one-half of the cases of
BSI [2]. A risk score was recently derived to predict the
prognosis of patients at the time of diagnosis with Gram-
negative BSI based on acute severity of illness as summarized
in the Pitt bacteraemia score, source of infection and two
major comorbid medical conditions that were independently
associated with mortality (Table 1). The BSI mortality risk
score (BSIMRS) had high prognostic ability to predict mortality
in adult patients with Gram-negative BSI that were treated at
tertiary care medical centres [3].
The aim of the current study was to provide external
validation for the BSIMRS in a population-based cohort to
account for the potential limitations of the derivation cohort
that were related to the referral sample, including under-
representation of patients at the extremes of age and
relatively high prevalence of cancer and liver cirrhosis. We
used a population-based cohort of patients with BSI due to
Escherichia coli and Pseudomonas aeruginosa, the most com-
mon Gram-negative bacilli among Enterobacteriaceae and
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lactose non-fermenters, respectively. The primary aim
was to evaluate the ability of the BSIMRS to predict
28-day mortality in this population-based cohort. Secondary
aims included examination of other short-term (7-day
and 14-day mortality) and long-term outcomes (1-year
mortality).
Methods
Setting
Olmsted County is located in southeastern Minnesota and
has a population of 124 277 according to the 2000 census
(US Census Bureau, Olmsted County QuickFacts—http://
quickfacts.census.gov, accessed 1 October, 2012). The pop-
ulation characteristics of Olmsted County residents are
similar to those of USA non-Hispanic whites [4,5]. The
Rochester Epidemiology Project is a unique medical records-
linkage system that encompasses healthcare delivered to
Olmsted County, Minnesota, residents. The microbiology
laboratories at Mayo Medical Center and Olmsted Medical
Center are the only two laboratories in Olmsted County.
These two medical centres are geographically isolated from
other urban centres as previously described [4,6], which
increases the likelihood that residents get their healthcare at
the local facilities rather than seeking care at a distant
geographic location.
Deﬁnitions
The primary source of BSI was deﬁned using the Centers for
Disease Control and Prevention criteria [7]. Patients with
cancer were deﬁned as those with current diagnosis of
malignant tumour, excluding skin basal and squamous cell
carcinoma. Liver cirrhosis was deﬁned based on clinical,
laboratory, ultrasonography or histopathology results, when
available [8].
Case ascertainment
All residents of Olmsted County, Minnesota, were eligible for
inclusion as we used complete enumeration of the Olmsted
County population from 1 January 1998 to 31 December 2007.
After the institutional review boards of Mayo Medical Center
in Rochester, Minnesota, and Olmsted Medical Center had
approved the study, we used the microbiology laboratory
databases at both institutions to identify all patients with E. coli
and P. aeruginosa BSI during the study period. All patients were
considered for inclusion in the study, regardless of the status
of hospitalization, site of infection acquisition, admission
location during hospitalization, or primary admitting service.
Using the Rochester Epidemiology Project tools, we identiﬁed
residents of Olmsted County, Minnesota, for inclusion in the
study and excluded those who lived outside Olmsted County
at the time of BSI. The primary investigator (MNA) reviewed
the medical records of all patients to conﬁrm the diagnosis,
determine patient residency status and obtain clinical features
and outcome. The detailed case ascertainment methods are
described elsewhere [9,10]. As both the derivation and
validation cohorts were located in the same geographic area,
we excluded patients who were previously included in the
derivation cohort to avoid potential overlap.
Blood cultures were processed using standard microbiology
techniques according to the CLSI. The detailed blood culture
methods used are described elsewhere [2,11]. The microbi-
ology laboratories at the Mayo Medical Center in Rochester,
Minnesota, and Olmsted Medical Center are certiﬁed by the
College of American Pathologists.
Statistical analysis
BSIMRS was calculated by adding the allocated points for
variables present in each patient (Table 1). Logistic regression
was used to examine the association between BSIMRS and
28-day mortality. Odds ratios (OR) with 95% conﬁdence
intervals (CI) were calculated to indicate the strength of
association between BSIMRS and mortality.
The area under a receiver operating characteristic curve
(AUC), was used to quantify the discriminative ability of the
BSIMRS, with a value of 0.5 denoting random predictions and a
value of 1.0 denoting perfect predictions. To visually assess
calibration, deciles of predicted risk of mortality were plotted
from the risk score model by the actual fraction of patients
who died within 28 days. Predicted probabilities obtained
directly from the scoring model were plotted by risk score
values to visualize the estimated risk of mortality. The
sensitivity, speciﬁcity and negative predictive value (NPV)
were calculated from the receiver operating characteristic
curve for the best cut point in the BSIMRS for 7-, 14-, 28- and
365-day mortality. Only patients who were followed for the
TABLE 1. Bloodstream infection mortality risk score
Variable
Point
allocation
Malignancy 3
Liver cirrhosis 4
Source of infection other than urinary tract or central venous
catheter
4
Pitt bacteraemia scorea
0–1 0
2–3 2
≥4 5
aPitt bacteraemia score was calculated based on temperature (35.1–36°C or 39.0–
39.9°C: 1 point, ≤35 or ≥40°C: 2 points), blood pressure (hypotension: 2 points),
mental status (disorientation: 1 point, stupor: 2 points, coma: 4 points), respiratory
status (mechanical ventilation: 2 points) and cardiac status (cardiac arrest: 4
points). The worst reading was recorded on the day the ﬁrst positive blood
culture was obtained or the day before for nosocomial bloodstream infections.
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entire duration of the interval (7, 14, 28 days and 1 year,
respectively) were included in the statistical analysis. Patients
who were lost to follow up before the end of the interval
duration were excluded from the analysis of that particular
interval. Death was conﬁrmed by reviewing medical records
and the Minnesota death registry database.
JMP (version 10.0, SAS Institute Inc, Cary, NC) was used for
statistical analysis. The level of signiﬁcance for statistical testing
was deﬁned as p <0.05 (two-sided) unless otherwise speciﬁed.
Results
Overall, 508 unique Olmsted County residents with ﬁrst
episodes of E. coli and P. aeruginosa BSI were identiﬁed during
the 10-year study period. After exclusion of 84 patients who
were previously included in the derivation cohort, 424
individuals with BSI were included in the current study. The
mean age was 68 years (range 0–99 years) and 280 (66%)
were female. The baseline clinical characteristics of patients
are shown in Table 2. Overall, 419 (99%) of patients in this
cohort were followed for at least 28 days from the time blood
cultures were obtained. The overall 28-day mortality following
BSI was 9% (38/419).
There was nearly 56% increase in 28-day mortality for each
point increase in BSIMRS (OR 1.56, 95% CI 1.40–1.78). The
AUC for the risk score model was 0.86 (Fig. 1). Model
calibration looked satisfactory because the observed outcomes
appeared fairly close to the predictions (Fig. 2). The predicted
28-day mortality by BSIMRS is shown in Fig. 3.
A BSIMRS ≥5 had a sensitivity of 74% and a speciﬁcity of
87% to predict 28-day mortality with an NPV of 97%. There
was a substantial increase in 28-day mortality as the BSIMRS
increased from <5 (reference) to 5–9 (OR 15.09, 95% CI 6.66–
36.69) to ≥10 (OR 217.33, 95% CI 32.77–4337.71).
The overall 7- and 14- day mortality rates were 6% (24/422)
and 7% (31/421), respectively. The BSI risk score performed
well in predicting 7- and 14-day mortality with AUC of 0.85 for
both. A BSI risk score ≥5 had comparable sensitivity, speciﬁcity
and NPV to predict 7- and 14-day mortality as those for 28-day
mortality (Table 3).
TABLE 2. Clinical characteristics of patients with blood-
stream infection
Variable (n = 424)
Age in years, median (range) 68 (0–99)
Female gender, n (%) 280 (66)
White ethnicity, n (%) 375 (88)
Years of educationa, median (range) 12 (0–20)
Diabetes mellitus, n (%) 99 (23)
Cancer, n (%) 61 (14)
Liver cirrhosis, n (%) 9 (2)
Primary source of infection, n (%)
Urinary tract 332 (78)
Gastrointestinal tract 25 (6)
Respiratory tract 24 (6)
Central venous catheter 3 (1)
Other, n (%) 8 (2)
Unknown, n (%) 32 (8)
Pitt bacteraemia score, n (%)
0–1 326 (77)
2–3 56 (13)
≥4 38 (9)
Microbiology, n (%)
Escherichia coli 385 (91)
Pseudomonas aeruginosa 39 (9)
Site of infection acquisition, n (%)
Community-acquired 235 (55)
Healthcare-associated 145 (34)
Nosocomial 44 (10)
aTotal years of education are provided for 346 adults with available data.
FIG. 1. Receiver operating characteristic plot of the bloodstream
infection mortality risk score model of 28-day mortality. *Area under
the curve for the bloodstream infection mortality risk score
model = 0.86.
FIG. 2. Calibration plot of bloodstream infection mortality risk score
model for 28-day mortality. *The observed frequency of 28-day
mortality plotted by deciles of predicted probability from the
bloodstream infection mortality risk score model (black line). Perfect
calibration is represented by the grey y = x line.
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Nearly 92% (391/424) of patients in this cohort were
followed for at least 1 year. The overall 1-year mortality was
23% (89/391). The BSIMRS predicted 1-year mortality with an
AUC of 0.81. A BSIMRS ≥3 had reasonable sensitivity,
speciﬁcity and NPV to predict 1-year mortality (Table 3).
Discussion
Despite the notable differences between the derivation and
validation cohorts (see Supporting information, Table S1), the
BSIMRS estimated mortality with high discrimination in both
referral and population-based settings.
The BSIMRS performed well in predicting a variety of
short-term outcome measures, ranging from 7- to 28-day
mortality. It is conceivable that the best AUC was observed
for 28-day mortality, for which the risk score was derived.
However, the BSIMRS had higher NPV for 7-day than that for
28-day mortality because of the higher overall survival in the
former interval.
Examination of long-term outcome is a unique feature of
this population-based study. The BSIMRS had relatively high
discrimination to predict 1-year mortality. However, the
AUC was higher for 28-day mortality and other short-term
outcomes compared with 1-year mortality. It is not surprising
that the best cut point for 1-year mortality was 3 rather than 5,
as in short-term outcomes. Malignancy (3 allocated points in
the risk score) was likely a contributor to late deaths between
28 and 365 days from BSI. Including major host factors such as
cancer and liver cirrhosis distinguished the BSIMRS from other
acute severity of illness scores and allowed for prediction of
long-term in addition to short-term outcomes [12,13].
The BSIMRS demonstrates that BSI is a spectrum of illness.
Patients with BSI have tremendous differences in prognosis,
ranging from an estimated short-term mortality of nearly 1% at
one end to over 80% at the other end of the spectrum (Fig. 3).
The BSIMRS provides a simple tool to predict the outcome of
patients at the time of diagnosis of Gram-negative BSI. This
wide variation in survival and its predictability has both clinical
and research implications.
The simplicity of the BSIMRS and relatively limited number
of variables included make it an attractive choice. The Pitt
bacteraemia score is a measure of the acute severity of illness
and is primarily based on readily available clinical variables such
as temperature, blood pressure, and respiratory, cardiac and
FIG. 3. Predicted probability of 28-day mortality by bloodstream infection mortality risk score. *Size of marker for point estimates is weighted
approximately by the relative number of subjects with corresponding risk score.
TABLE 3. Performance of bloodstream infection mortality
risk score for various short- and long-term outcomes
Outcome AUC
Best
cut
point
Sensitivity
(%)
Speciﬁcity
(%)
NPV
(%)
Complete
follow-up
(%)
7-day
mortality
0.85 ≥5 78 85 99 100
14-day
mortality
0.85 ≥5 77 86 98 99
28-day
mortality
0.86 ≥5 74 87 97 99
1-year
mortality
0.81 ≥3 77 76 92 92
AUC, area under receiver operating characteristic curve; NPV, negative predictive
value.
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mental statuses [14]. The primary source of infection is a
reﬂection of the inoculum of infection. BSI is categorized into
low inoculum such as urinary or central venous catheter (CVC)
infections versus other high inoculum infections [15–22]. To
maintain simplicity, the exact source of infection does not
need to be established to execute the score as long as urinary
and CVC infections are ruled in or out by history, physical
examination, urinalysis and time to positivity of blood cultures
drawn peripherally and through CVC [3,23]. The last two
components of the BSIMRS, cancer and liver cirrhosis, provide
an assessment of the host’s ability to survive BSI [24–28].
The BSI risk score enables treating clinicians to better
estimate the prognosis of patients with Gram-negative BSI,
which could be valuable in clinical management and providing
patient/family expectations. For example, a patient with liver
cirrhosis and Gram-negative BSI secondary to spontaneous
bacterial peritonitis (BSIMRS of 8) may present without high
fever, hypothermia, hypotension or respiratory failure. Nev-
ertheless, such a patient has a relatively high predicted 28-day
mortality of nearly 40% as estimated by BSIMRS (Fig. 3), which
is also consistent with the results of a recent large systematic
review [28]. It would be reasonable to closely monitor such
patients with high-predicted mortality in an intensive or
intermediate care unit to allow quicker interventions in case
of clinical deterioration. On the other hand, a serious
conversation with the family regarding prognosis and expec-
tations may need to be established early in patients with
BSIMRS ≥10 because of the poor prognosis in this category.
Estimation of mortality in patients with Gram-negative BSI
may also have an impact on empirical antimicrobial therapy.
The threshold for aggressive antimicrobial therapy may need
to be lower in patients with BSMRS ≥5compared with those
with a score <5 to ensure appropriate therapy in patients with
relatively high predicted mortality. Future studies evaluating
the impact of inappropriate antimicrobial therapy on outcome
of patients with Gram-negative BSI after stratiﬁcation by
BSIMRS would provide valuable information in this regard.
In addition to its clinical utility, the BSIMRS may be a useful
tool in clinical research. The overall decline in mortality
following Gram-negative BSI over the past two decades has left
many small studies, particularly those focused on one microor-
ganismor a speciﬁc antimicrobial resistancemechanism,without
adequate power to adjust for all individual variables that are
known to be associated with mortality in a multivariable model.
The BSIMRS provides clinical investigators with an alternative
option to adjust for the risk score as one variable because it
includes all variables that are independently associated with
mortality, after adjustments for age and other relevant variables
to the study population. The BSIMRS may also be used as a
method of randomization or stratiﬁcation in clinical trials.
The primary strengths of this study are the population-based
design, which decreases the possibility that referral bias affects
the results, large sample size, and near-complete 28-day follow
up facilitated by the Rochester Epidemiology Project.
The study has some limitations. First, this was a retrospec-
tive cohort study. A prospective validation with real-time
collection of variables would have been ideal. However, the
database was near complete due to availability of electronic
medical records and timing of included variables was clearly
predeﬁned before data collection. Second, the population of
Olmsted County consists mainly of middle class whites;
therefore, our study results may be generalized only to
communities with similar population characteristics. Third, our
data were derived from one geographic area. The results of
studies from multiple geographic locations might provide a
more generalizable application. Finally, the validation cohort
included patients with BSI predominately due to E. coli and, to
a lesser extent, P. aeruginosa, rather than all Gram-negative
bacilli as in the derivation cohort. However, this is less likely to
inﬂuence the results because E. coli and P. aeruginosa are the
ﬁrst and third most common Gram-negative bloodstream
isolates and when combined, account for >60% of all
Gram-negative BSI in our population [11].
In summary, The BSIMRS had a high prognostic ability to
predict mortality in a population-based cohort that included
patients in all age groups who had a relatively low prevalence
of cancer and liver cirrhosis. The robust performance of the
BSIMRS in both the derivation and validation cohorts provides
assurance of the risk score’s utility in both clinical settings and
research investigations in the future.
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